Searched for
BIOSCIENCES AND RESEARCH
Ben Lamm and Colossal Biosciences: The billionaire tech founder behind the $10 billion plan to bring back extinct animalsTech entrepreneur Ben Lamm is spearheading Colossal Biosciences, a company aiming to bring back extinct species like the woolly mammoth thr...- Societe General, Prudential, others buy 3 per cent stake in Anthem Biosciences for Rs 1,275 crGlobal investors including Societe Generale and Prudential Hong Kong, alongside Indian mutual funds and insurance companies, have bought a ...
- Quant Mid Cap Fund adds Adani Energy and 4 others, exits Paytm and 3 more stocks in MayQuant Mid Cap Fund, managed by Sandeep Tandon, has strategically adjusted its portfolio in May. The fund added Adani Energy and four other ...
- Ashoka University appoints Professor Rishikesha T. Krishnan as its next vice-chancellorAshoka University has appointed Professor Rishikesha T. Krishnan as its next Vice-Chancellor, effective August 1, 2026. A distinguished sch...
- Several red flags emerge as SpaceX IPO hawks Elon Musk's Mars dreamSpaceX's bold Mars vision faces scientific doubts. Experts highlight engineering challenges and human biology unknowns. Colonizing Mars pre...
- Intel CEO unveils AI innovations and partnerships at mega tech event in TaiwanIntel unveiled new AI-focused technologies, strategic collaborations, and next-generation processors at Computex 2026. The company announce...
- FIIs pull out massive Rs 20,637 crore in single day on Friday. What led to this sharp exit?Foreign portfolio investors offloaded Indian equities worth a net Rs 20,637 crore on Friday, marking one of the sharpest single-day selloff...
- What AI’s entry into de-extinction research says about modern biologyArtificial intelligence is increasingly being used to process complex genetic data, enabling new approaches in biological research. This sh...
- Hantavirus scare a wake-up call: Why India must build its disease X defencesA recent hantavirus outbreak on a cruise ship echoes past pandemic scares. Experts warn Disease X, a future unknown pathogen, is a near cer...
- Shastra VC launches $100 million fund to back deeptech, AI startupsThe Bengaluru-based firm said the new vehicle will invest between $500,000 and $3 million in IP-led firms across these sectors. The launch ...
- Federal Bank, Indian Bank, MCX & Nalco in MSCI GlobalGlobal index provider MSCI has announced significant changes to its indices. Federal Bank, Indian Bank, Multi Commodity Exchange of India, ...
- Tata group’s Impetis out-licenses arthritis and autoimmune drugs to VyomeIn a significant move for medical innovation, Impetis Biosciences, a subsidiary of Tata group, has teamed up with Vyome Holdings from the U...
- MSCI rejig: MCX, Indian Bank included, but RVNL, Kalyan Jewellers outMSCI’s May 2026 index rejig kept India’s overall representation in the MSCI Standard Index unchanged at 165 stocks, even as four companies,...
- Chinese medicines bring relief to India’s cancer patientsIndia’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...
- US market today: Biotech firm Odyssey hits nearly $900 million valuation as shares rise in Nasdaq debutOdyssey Therapeutics debuted on Nasdaq with an 11.1% surge, reaching a $899.9 million valuation. The autoimmune disease specialist successf...
- The real Jurassic Park is happening: Woolly mammoths are returning and that's not even the biggest news — here's what else is comingExtinct animals coming back: Scientists are pursuing de-extinction, aiming to bring back species like the woolly mammoth and bluebuck. The ...
- Anthem BioSciences shares jump 4% as Citi initiates with Buy rating. Check target, upside potentialShares of Anthem BioSciences rose after Citi initiated coverage with a Buy rating and a target price of ₹870, implying over 20% upside. Ana...
- Private equity fund True North acquires minority stake in Bengaluru-based Anthem BioSet up by ex-Biocon executive Ajay Bharadwaj, Rs.1200-crore Anthem Biosciences competes with Biocon owned Syngene International and Hyderab...
- GVK Biosciences to buy Chennai based Vanta Bio for $5millionVanta Bio is into offering toxicology evaluation services for pharmaceutical, biotech, food supplements and feed additives industries.
- GVK Biosciences, Onconova Therapeutics ink pact to develop cancer drugsThe Hyderabad-based firm and Onconova have entered into a JV to develop new drugs for cancer, GVK Biosciences said in a statement.
Load More
